FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 10x Genomics's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN442 Mil. 10x Genomics's Revenue for the
three
months ended in Mar. 2026 was MXN2,720 Mil. Therefore, 10x Genomics's FCF Margin % for the quarter that ended in Mar. 2026 was 16.26%.
The historical rank and industry rank for 10x Genomics's FCF Margin % or its related term are showing as below:
MEX:TXG'
s FCF Margin % Range Over the Past 10 Years
Min: -85.76 Med: -20.33 Max: 20.24
Current: 19.05
During the past 9 years, the highest FCF Margin % of 10x Genomics was 20.24%. The lowest was -85.76%. And the median was -20.33%.
MEX:TXG's FCF Margin % is ranked better than 91.78% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 3.34
vs MEX:TXG: 19.05
10x Genomics FCF Margin % Related Terms
10x Genomics FCF Margin % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TXG vs WAY, DOCS, HNGE: FCF Margin % Comparison
For the Health Information Services subindustry, 10x Genomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (MEX:TXG) has a FCF Margin % of 16.26% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #55 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 8.2%.
Is 10x Genomics' FCF Margin % too high?
10x Genomics' current FCF Margin % is 16.26%. The Healthcare Providers & Services industry median FCF Margin % is 3.34. 10x Genomics' value of 16.26% is 386.8% above this industry median. Based on the distribution chart, 10x Genomics ranks #55 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' FCF Margin % compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #55 out of 669 companies for FCF Margin %. This places 10x Genomics in the top 8% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.34. 10x Genomics' value of 16.26% is 386.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.34, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current FCF Margin % of 16.26% is 386.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current FCF Margin % is 16.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current FCF Margin % of 16.26%. The stock's GF Value™ is MXN200.14, compared to a current price of MXN335.54 — trading 67.7% above its estimated fair value. The current FCF Margin % is 16.26% and 386.8% above the Healthcare Providers & Services industry median of 3.34. 10x Genomics' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current FCF Margin % is 16.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 67.7% above its estimated GF Value™ of MXN200.14.
Key valuation signals for MEX:TXG:
FCF Margin %: 16.26%
GF Value™: MXN200.14 vs. price of MXN335.54 (67.7% above fair value)
Industry Position: 386.8% above the Healthcare Providers & Services median (#55 of 669)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
68GF Score
Get the complete analysis for MEX:TXG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
